No Data
No Data
No Data
No Data
No Data
Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target
Wedbush analyst Robert Driscoll reiterates Tyra Biosciences with a Outperform and maintains $28 price target.
Analyst UpgradesMar 21 20:47
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Raises Price Target to $23
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Tyra Biosciences with a Buy and raises the price target from $19 to $23.
Analyst UpgradesMar 20 18:42
Tyra Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 42.86% HC Wainwright & Co. $19 → $23 Reiterates Buy → Buy 12/29/2023 67.7% Wedbush $27 → $27 Re
BenzingaMar 20 18:41
Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress
Yahoo FinanceMar 20 09:01
Tyra Biosciences Inc Files For Resale Of Up To 15.4M Shares By The Selling Securityholders
Tyra Biosciences Inc Files For Resale Of Up To 15.4M Shares By The Selling Securityholders
BenzingaMar 20 05:00
Tyra Biosciences Q4 Net Loss Widens
Tyra Biosciences (TYRA) reported a Q4 net loss late Tuesday of $0.53 per diluted share, compared with a loss of $0.31 per share a year earlier. Analysts polled by Capital IQ expected a loss of $0.48.
MT NewswiresMar 20 04:53
No Data
No Data